DNA Methylation Inhibitors in the Treatment of Leukemias, Myelodysplastic Syndromes and Hemoglobinopathies: Clinical Results and Possible Mechanisms of Action

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

1997 • 4,416 citations

Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia

1997 • 1,960 citations

Cellular differentiation, cytidine analogs and DNA methylation

1980 • 1,803 citations

Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

1995 • 1,353 citations

DNA methylation in the human γδβ-globin locus in erythroid and nonerythroid tissues

1980 • 634 citations

Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine.

1982 • 575 citations

5-Azacytidine Selectively Increases γ-Globin Synthesis in a Patient with β⁺Thalassemia

1982 • 496 citations

Chronic myelogenous leukemia: a concise update

1993 • 453 citations

Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies.

1997 • 420 citations

Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.

1998 • 376 citations

Methylation of the p15INK4b Gene in Myelodysplastic Syndromes Is Frequent and Acquired During Disease Progression

1998 • 352 citations

Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis

1997 • 320 citations

Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex.

1983 • 270 citations

Hypermethylation of the p15INK4B Gene in Myelodysplastic Syndromes

1997 • 260 citations

Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia.

1970 • 260 citations

5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia

1983 • 248 citations

Age‐related incidence and other epidemiological aspects of myelodysplastic syndromes

1992 • 235 citations

Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.

1993 • 222 citations

Pilot phase l-ll study on 5-aza-2??-deoxycytidine (Decitabine) in patients with metastatic lung cancer

1997 • 209 citations

Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome

1997 • 201 citations

Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.

1997 • 194 citations

Hemimethylated duplex DNAs prepared from 5-azacytidine-treated cells

1981 • 190 citations

Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60).

1983 • 183 citations

Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia

1981 • 183 citations

5-Azacytidine

1976 • 177 citations

5-Aza-2'-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias

1984 • 173 citations

Inhibition of tumorigenesis by a cytosine–DNA, methyltransferase, antisense oligodeoxynucleotide

1997 • 171 citations

Nucleic acids components and their analogues. LI. Synthesis of 1-glycosyl derivatives of 5-azauracil and 5-azacytosine

1964 • 164 citations

Clinical trial on 5-AZA-2′-deoxycytidine in patients with acute leukemia

1985 • 141 citations

Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia

1997 • 140 citations

A Phase II Study of 5-AZA-2'Deoxycytidine (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer

1998 • 139 citations

Changes in phenotypic expression in embryonic and adult cells treated with 5-azacytidine

1982 • 137 citations

5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends.

1993 • 135 citations

Treatment with Azacitidine of Patients with End-Stage β-Thalassemia

1993 • 126 citations

Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia.

1999 • 121 citations

The EORTC early clinical trials cooperative group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas

1987 • 119 citations

Inhibition of DNA methylation in L1210 leukemic cells by 5-aza-2'-deoxycytidine as a possible mechanism of chemotherapeutic action.

1983 • 118 citations

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

1993 • 118 citations

Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients.

1986 • 118 citations

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase-III intergroup study

1992 • 113 citations

A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial

1984 • 108 citations

Incorporation of 5-Aza-2'-deoxycytidine-5'-triphosphate into DNA. Interactions with mammalian DNA polymerase alpha and DNA methylase.

1983 • 102 citations

Synthesis of a 2-deoxy-D-ribofuranosyl-5-azacytosine

1964 • 94 citations

5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia

1983 • 93 citations

5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia

1976 • 89 citations

Molecular, cellular and animal pharmacology of 5-AZA-2′-deoxycytidine

1985 • 89 citations

A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).

1997 • 88 citations

Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results.

1993 • 84 citations

Perturbations in the erythroid marrow progenitor cell pools may play a role in the augmentation of HbF by 5-azacytidine

1984 • 82 citations

5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin.

1985 • 77 citations

THE ACTIVITY OF A NEW ANTIMETABOLITE, 5-AZACYTIDINE, AGAINST LYMPHOID LEUKAEMIA IN AK MICE.

1964 • 76 citations

5-azacytidine in acute leukemia

1978 • 72 citations

The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia

1991 • 69 citations

Activation of the retinoic acid receptor ?? gene by 5-aza-2???-deoxycytidine in human DLD-1 colon carcinoma cells

1997 • 68 citations

Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2′-deoxycytidine

1985 • 67 citations

5-Azacytidine increases HbF production and reduces anemia in sickle cell disease: dose-response analysis of subcutaneous and oral dosage regimens

1985 • 62 citations

5-AZA-2′-deoxycytidine therapy in patients with acute leukemia inhibits DNA methylation

1984 • 61 citations

5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.

1989 • 59 citations

Improved remission induction rate with D‐ZAPO but unimproved remission duration with addition of immunotherapy to chemotherapy in previously untreated children with ANLL

1979 • 55 citations

Azacitidine: 10 years later.

1987 • 55 citations

Evaluation of continuous infusion low‐dose 5‐azacytidine in the treatment of myelodysplastic syndromes

1991 • 53 citations

Perturbations in the erythroid marrow progenitor cell pools may play a role in the augmentation of HbF by 5-azacytidine

1984 • 53 citations

Carcinogenicity and haemoglobin synthesis induction by cytidine analogues

1988 • 53 citations

Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: A southwest oncology group study

1981 • 51 citations

Decitabine studies in chronic and acute myelogenous leukemia.

1997 • 40 citations

DNA alkali-labile sites induced by incorporation of 5-aza-2'-deoxycytidine into DNA of mouse leukemia L1210 cells.

1985 • 39 citations

Pharmacodynamic and DNA methylation studies of high-dose 1-?-d-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia

1989 • 35 citations

Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.

1992 • 35 citations

5-azacytidine in childhood leukemia.

1971 • 33 citations

Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213.

1982 • 31 citations

Comparison of antineoplastic activity of cytosine arabinoside and 5-aza-2′-deoxycytidine against human leukemic cells of different phenotype

1990 • 29 citations

5‐AZACYTIDINE TREATMENT IN A β^o‐THALASSAEMIC PATIENT UNABLE TO BE TRANSFUSED DUE TO MULTIPLE ALLOANTIBODIES

1989 • 27 citations

Mitoxantrone and 5‐azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study

1993 • 25 citations

Phase II study of 5-Aza-2′-deoxycytidine in advanced ovarian carcinoma

1990 • 24 citations

Effect of 5-Azacytidine on Gene Expression in Marrow Stromal Cells

1989 • 21 citations

Studies of decitabine with allogeneic progenitor cell transplantation.

1997 • 17 citations

Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia.

1990 • 16 citations

Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).

1995 • 16 citations

Effect of 5-azacytidine on gene expression in marrow stromal cells.

1989 • 15 citations

Response to 5-azacytidine in patients with refractory acute nonlymphocytic leukemia and association with chromosome findings

1982 • 14 citations

Effect of 5‐azacytidine treatment on mouse embryonal carcinoma cells

1983 • 13 citations

Low-Dose Ara-C in Myelodysplastic Syndromes (MDS) and Acute Leukemia Following MDS: Proposal for a Predictive Model

1994 • 11 citations

Cytokine mediated growth inhibition of HTLV-I infected transformed human lymphocytes.

1997 • 11 citations

Long-Term Outcome of Postremission Chemotherapy for Adults with Acute Myeloid Leukemia Using Different Dose-Intensities

1994 • 10 citations

Chromosome changes associated with growth potential of HTLV-I infected human lymphocytes.

1997 • 6 citations

Treatment of refractory adult acute leukemia with 5-azacytidine plus beta-2'-deoxythioguanosine.

1979 • 5 citations

Cytogenetic remissions in high-risk myelodysplastic syndrome: Results in 124 patients treated with low-dose 5-aza-2 '-deoxycytidine (Decitabine), a DNA methylation inhibitor.

2000 • 3 citations

Deleted Work

1955 • 0 citations